ABSTRACT
Objective To investigate the significance of the soluble Apo-1/Fas(sApo-1/Fas) in differentiating tuberculous and malignant pleural effusion.Methods The level of sApo-1/Fas was detected by enzyme linked immunosorbent assay(ELISA).in serum and pleural effusion of 50 cases with malignant pleural effusion and 48 cases with tuberculous pleural effusion.Results The level of sApo-1/Fas in the serum and pleural effusion of malignant pleural effusion patients were ( 16.3 ± 2.5 ) μg/L and ( 38.6 ± 13.5) μg/L,significantly higher than those of tuberculous patients with pleural effusion( all P ＜ 0.05 ).The difference of rates of serum and pleural effusion in malignant pleural effusion and tuberculous pleural effusion patients was significant( P ＜ 0.05 ).The sensitivity,specificity and accuracy of sApo-1/Fas in serum and malignant pleural effusion were 66.0％ and 93.8％ and 79.6％.Conclusion The detecting of sApo-1/Fas may play some role in differentiating tuberculous and malignant pleural effusion.
ABSTRACT
ObjectiveTo explore the levels and clinical significance of osteopontin (OPN) in serum of patients with non-small cell lung cancer (NSCLC).MethodsOPN levels of 102 cases of NSCLC,42 cases of benign lung disease and 30 cases of healthy control were measured by enzyme-linked immunosorbent assay(ELISA).ResultsThe serum OPN levels of NSCLC were significantly higher than those of benign lung disease group and healthy control group (P＜0.01).The levels of OPN in serum were compared between different gender,age,histological differentiation and pathological type groups,but there were no significant difference (P＞0.05).The serum OPN levels of Ⅲ - Ⅳ stage NSCLC patients,with lymph node metastasis,before operation patients,recrudescent patients,survival below 3 years patients were relatively higher than that in the patients with Ⅰ - Ⅱ stage,without lymph node metastasis,after operation,no recrudescent,survival over 3 years patients,and the differences were significant (P＜0.01).ConclusionsOPN levels in serum reflected the severity of the disease,which can be used to determine the effects of surgery and monitor recurrence and evaluate prognosis.
ABSTRACT
ObjectiveTo detect serum soluble B7-H4 (sB7-H4) levels in patients with non-small cell lung cancer ( NSCLC ) and explore its clinical significances.MethodsThe sB7-H4 levels the sera of in 102 NSCLC patients,60 benign lung disease patients and 90 healthy controls were determined by ELISA.The relation between serum sB7-H4 levels and NSCLC of pathological staging was analyzed by use of t test.ResultsThe serum sB7-H4 levels in NSCLC,benign lung disease and heathy control groups were (45.61 ±5.67 ),( 30.14 ± 3.51 ) and ( 28.52 ± 4.76 ) μg/L,respectively.The levels of NSCLC group were significantly higher than those of benign lung disease and healthy control groups ( t =2,59 and 3.61,P ＜ 0.05 ).The serum sB7-H4 levels of Ⅲ/IV stage NSCLC patients ( 63.93 t 4.76 ) μgL,with lymph node metastasis (61.73 ±3.97) μg/L and before operation patients (63.29 ±6.19) μg/L were relatively higher thanthose inthe Ⅰ/Ⅱ stage(35.12 ± 3.88 )μg/L, without lymphnode metastasis (40.26 ± 5.39 ) μg/L,after operation ( 40.51± 4.08 ) μg/L.There were significant difference ( t =6.78,5.73 and 3.67,P ＜ 0.05 ).Conclusions Serum sB7-H4 of NSCLC patients increases significantly and correlates with clinical stages and therapeutic conditions.Detecting on sB7-H4 is helpful for lung cancer diagnosis and therapeutic effect evaluation.
ABSTRACT
Objective To detect the expression of histone deacetylase 6 (HDAC6) and its significance in non-small cell lung cancer (NSCLC).Methods The expression of HDAC6 was measured by SP staining in 70 cases of NSCLC and 18 cases of normal lung tissues.Results Positive rate of HDAC6 immunostaining in NSCLC was 58.57％,which was significantly higher than 16.67％ in normal lung tissues(P ＜0.01 ).No correlation was found between HDAC6 expression and the age,sex,differentiated level,histological type ( P ＞0.05).But the expression level of HDAC6 was closely related to clinical stage and lymph node metastasis in NSCLC patients ( P ＜ 0.05 ).Conclusion HDAC6 over expression may be related to the pathogenesis and development of NSCLC.
ABSTRACT
<p><b>BACKGROUND AND OBJECTIVE</b>Wnt1 protein is the first factor in Wnt signaling pathway. It has been proven that high expression of Wnt1 protein was associated with malignant proliferation in many tumors. The aim of this study is to investigate the correlation between Wnt1 protein overexpression, clinicopathologic features and survival in resected non-small-cell lung cancer (NSCLC).</p><p><b>METHODS</b>Immunohistochemical staining of Envision was applied to investigate the expression of Wnt1 protein in specimens of 115 NSCLC and 19 benign pulmonary diseases. The correlation between the Wnt1 protein in specimens of 115 NSCLC and clinicopathologic features was analysed with chi2 test, and the correlation between the Wnt1 protein expression and the patient survival was evaluated with Kaplan-Meier survival curve and Cox regression.</p><p><b>RESULTS</b>The positive rate ofWnt1 protein in specimens of NSCLC was 62.6%, which was significantly higher than 31.6% of benign pulmonary diseases (chi2 = 4.474, P = 0.034). But it was not correlated with clinicopathologic features. Kaplan-Meier survival analysis and Log-rank test suggested that patients with Wnt1 protein overexpression had poor prognosis (P = 0.003). And Cox regression suggested Wnt1 protein expression was an independent prognostic factor of NSCLC.</p><p><b>CONCLUSION</b>The expression of Wnt1 was remarkably higher in specimens of resected NSCLC than that in benign pulmonary diseases. Overexpression of Wnt1 protein in NSCLC was correlated with prognosis and can be served as an independent prognostic factor of NSCLC.</p>
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Carcinoma, Non-Small-Cell Lung , Chemistry , Mortality , Pathology , Immunohistochemistry , Lung Neoplasms , Chemistry , Mortality , Pathology , Prognosis , Proportional Hazards Models , Signal Transduction , Wnt1 Protein , PhysiologyABSTRACT
Objective To investigate the biodistribution of intratumoral administerd~(131)Ⅰ-labeled human-mouse chimeric monoclonal antibody (chTNT) in patients with advanced lung carcinoma. Methods Eleven patients enrolled had cytological and histological confirmed diagnoses of either stage Ⅲ b or stage Ⅳ inoperable lung carcinoma. Intratumoral injection was directed by thoracic CT-guided catheter using a multi-holed needle. The dose for each patient was 18.5 - 37 MBq/cm~3 tumor mass. Blood samples were drawn at different time intervals for up to 13 days, and urine samples were collected for up to 11 days after injection for pharmacokinetic studies. In vivo stability was examined by HPLC by analyzing serum and urine, which were found to contain~(131)Ⅰ-chTNT. Whole body images were taken for quantitative organ and tumor biodistribution studies. Results In all 11 patients,~(131)Ⅰ-chTNT was the major component of the radiolabel in serum. Within 96 hours after administration, it was 100% stable. Plasma disappearance curves of ~(131)Ⅰ-chTNT were best fit by a two-exponential model in all patients with T_(1/2kα) of (0. 89±0. 17) h and T_(1/2β) of (86.88 ± 25.97)h. Free Ⅰ was the only metabolite of Ⅰ-chTNT that appeared in urine. A biodistribution study demonstrated excellent localization of the radioactivity in tumors. The accumulated radioactivity in urine at 264 h was (58.37 △Corresponding author E-mail:chen. shaoliang@zs-hospital. sh. cn±17.45) % of the injection dose. There was (51.05±8.41)%ID ,~(131)Ⅰ-chTNT in the tumor at 30 min after injection, and the tumor/lung (T/N) ratio was 63.87 ± 25.71. It remained (3.47 ± 3.27) %ID at 264 h,and the T/N ratio was 9. 61 ± 11.00. Among the main target organs, accumulation of the radiolabeled antibody was mainly found in lungs, liver, heart, kidneys, spleen and thyroid.Conclusions Pharmacokinietics of ~(131)Ⅰ-chTNT follows a two-exponential model. According to its long preservation in tumor tissue, intratumoral injection of~(131)Ⅰ-chTNT is good for tumor therapy.
ABSTRACT
<p><b>BACKGROUND</b>To analysis and evaluate the efficacy of I-131 labeled chimeric TNT antibody ( ¹³¹I-chTNT MAb) targeting therapy in advanced lung cancer, and then choose the best way of administration.</p><p><b>METHODS</b>Forty-three patients with advanced lung cancer were treated by 3 different protocols using ¹³¹I-chTNT MAb. Their diagnosis was confirmed by histology and there were 30 cases in stage IIIB and 13 cases in stage IV, 32 cases were newly diagnosed and 11 cases were retreated. All patients were divided into three groups and treated with different methods: (1)iv infusion (n=22); (2) intratumoral injection (n=16); and (3) combination iv (25% of total dosage) and intratumoral (75%) infusion (n=5). All patients received radiolabeled MAb at a total dosage of 2.96×10⁷ Bq/kg on days 1 and 14.</p><p><b>RESULTS</b>There were 2 complete response (4.7%), and 11 partial response (25.6%), the total response rate was 30.2% (13/43) in all patients. For those patients receiving iv injection alone, the response rate was 9.1%. For those patients receiving intratumoral injection alone, the response rate was 56.3%. There was significant difference between them (P < 0.01 ). The main toxicity was reversible bone marrow suppression, 2 cases (4.7%) with grade III leukopenia and 3 cases (7.0%) grade III thrombocytopenia.</p><p><b>CONCLUSIONS</b>¹³¹I-chTNT has significant therapeutic effects on advanced lung cancer and the intratumoral injection is the best way of administration.</p>
ABSTRACT
Purpose:This report evaluate whether the single-agent therapy with vinorelbine (V group) may obtain a high response rate, with acceptable toxicity and improvement in survival and quality of life, comparing with the therapy with Kanglaite (a traditional Chinese medicine) (K group) and other supportive care among elderly patients.Methods:Forty patients with advanced NSCLC were included,20 of whom were allocated to receive continual infusional NVB 7.5mg/m 2 /24hr delivered via a central venous line on days 1-5, and NVB 7.5mg /m 2 was given as a 20 min intravenous infusion on days 1 every 3 weeks; 20 of whom were allocated to receive infusional Kanglaite 200 ml on days 1-20 every month. Patients received a minimum of two courses unless progressive disease was detected. Results:V group: CR 0,PR 7,CR+PR 35%(7/20), median survival time was 7.2 months and projected 1-year survival was 25%; K group:CR 0,PR2,CR+PR 10%(2/20),median survival time was 4.8 months and projected 1-year survival was 5%. Conclusions:In elderly patients with NSCLC, single-agent vinorelbine treatment is associated with better effective,better survival and improved quality of life than Kanglaite .Its toxicity is mild and acceptable.